Case Report: Remarkable breakthrough: successful treatment of a rare intracranial mesenchymal, FET::CREB fusion-positive tumor treated with patient-tailored multimodal therapy.

FET::CREB gene fusion challenging diagnosis immunotherapy intracranial mesenchymal tumor molecular analysis multimodal tailored therapy rare cancers

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2023
Historique:
received: 11 04 2023
accepted: 26 10 2023
medline: 14 12 2023
pubmed: 14 12 2023
entrez: 14 12 2023
Statut: epublish

Résumé

Intracranial mesenchymal tumors are a rare type of neoplasm (0.3% of all soft tissue tumors) characterized by a fusion of a This case describes a 27-year-old woman with unconventional extracranial metastatic sites of myxoid intracranial mesenchymal tumor Our case sheds light on the importance of precision medicine and tailored therapy to explore new treatment opportunities for rare or unknown tumor entities.

Sections du résumé

Background UNASSIGNED
Intracranial mesenchymal tumors are a rare type of neoplasm (0.3% of all soft tissue tumors) characterized by a fusion of a
Case description UNASSIGNED
This case describes a 27-year-old woman with unconventional extracranial metastatic sites of myxoid intracranial mesenchymal tumor
Conclusions UNASSIGNED
Our case sheds light on the importance of precision medicine and tailored therapy to explore new treatment opportunities for rare or unknown tumor entities.

Identifiants

pubmed: 38094610
doi: 10.3389/fonc.2023.1203994
pmc: PMC10716272
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1203994

Informations de copyright

Copyright © 2023 D’Antonio, Rossi, Giovannoni, Alaggio, Carai, Milano, Cacchione, Cancellieri, Gessi, Antonelli, Colafati, Megaro, Vennarini and Mastronuzzi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Federica D'Antonio (F)

Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.

Sabrina Rossi (S)

Department of Pathology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Isabella Giovannoni (I)

Department of Pathology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Rita Alaggio (R)

Department of Pathology, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Andrea Carai (A)

Unit of Neurorehabilitation, Department of Intensive Neurorehabilitation and Robotics, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Giuseppe M Milano (GM)

Department of Oncohematology, Hematopoietic Transplantation, and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Antonella Cacchione (A)

Department of Oncohematology, Hematopoietic Transplantation, and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Alessandra Cancellieri (A)

Institute of General Pathology, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.

Marco Gessi (M)

Institute of General Pathology, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.

Manila Antonelli (M)

Department of Radiological, Oncological, and Pathological Anatomy Sciences, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.

Giovanna S Colafati (GS)

Department of Diagnostic Imaging, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Giacomina Megaro (G)

Institute of General Pathology, Agostino Gemelli University Polyclinic (IRCCS), Rome, Italy.

Sabina Vennarini (S)

Radiotherapy Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.

Angela Mastronuzzi (A)

Department of Oncohematology, Hematopoietic Transplantation, and Cell Therapy, Bambino Gesù Children's Hospital (IRCCS), Rome, Italy.

Classifications MeSH